{
  "docId": "019de075-6448-707d-82ec-cbbeebb7feb3",
  "docSlug": "1eef6abd03697885c8a70f789c554a37",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 23,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The charts demonstrate efficacy in specific cell lines (KYSE70 and Cal27) with known genetic alterations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-6448-707d-82ec-cbbeebb7feb3/18",
  "deckHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3",
  "deckJsonHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3.json",
  "deckAnchorHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.51,
        "y": 0.245
      },
      "kind": "chart",
      "text": "Head and Neck Cancer tumor volume reduction",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7663507a-bc02-4c95-ba9c-5c439e73c69b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.09,
        "y": 0.245
      },
      "kind": "chart",
      "text": "Esophageal Cancer tumor volume reduction",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a7c1ff4-0cb2-4ab9-989d-4b43bdd2c94e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.09,
        "y": 0.87
      },
      "kind": "paragraph",
      "text": "KYSE70 cells (YES1 gene amplification is a known genetic alteration)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12bc877b-19a4-404f-888d-bd06d6427d68",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.51,
        "y": 0.87
      },
      "kind": "paragraph",
      "text": "Cal27 cells (Heterozygous FAT1 copy loss is a known genetic alteration)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee2e7428-8f9d-44fa-9fbe-6d9420e64a71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.03,
        "y": 0.16
      },
      "kind": "title",
      "text": "NXP900 demonstrated robust antitumor activity in xenograft models of squamous cell cancers",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30ee6186-3f19-4d78-b223-048f83b672c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Significant Single Agent Activity in Squamous Cell Cancers",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45354c4b-d548-44ae-b806-bc9924b6120b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 20,
      "from": 18,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "7e447b5d-aa17-4faf-88b6-6d6dc58b352b",
      "evidence": "The deck presents data on the significant single agent activity of NXP900 in squamous cell cancers.",
      "position": 1,
      "objective": "Present NXP900 as a potential game-changer in squamous cell cancers",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}